表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗联合CT引导下射频消融术对中晚期非小细胞肺癌患者的治疗效果

Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor targeted therapy combined CT guided radiofrequency ablation in patients with advanced non-small cell lung cancer

目的探讨表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗联合CT引导下射频消融术对中晚期非小细胞肺癌患者的治疗效果。方法根据治疗方法的不同将80例中晚期非小细胞肺癌患者分为对照组和观察组,每组40例,对照组患者采用CT引导下射频消融术联合化疗,观察组患者采用CT引导下射频消融术联合EGFR-TKI靶向治疗。比较两组患者的特异症状[欧洲癌症研究与治疗组织生命质量测定量表(EORTC QLQ-C30)]、肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)]水平、免疫功能指标(CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+))及不良反应发生情况。结果治疗后,两组患者疼痛、腹泻、疲劳、睡眠障碍、便秘、恶心呕吐评分均低于本组治疗前,观察组患者疼痛、腹泻、疲劳、睡眠障碍、便秘、恶心呕吐评分均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者血清CEA、CA125、NSE水平均低于本组治疗前,观察组患者血清CEA、CA125、NSE水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于本组治疗前,观察组患者CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者不良反应总发生率明显低于对照组(P﹤0.01)。结论EGFR-TKI靶向治疗联合CT引导下射频消融术可有效改善中晚期非小细胞肺癌患者的临床症状和免疫功能,降低肿瘤标志物水平,安全性较高,疗效确切。

Objective To investigate the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)targeted therapy combined CT guided radiofrequency ablation in patients with advanced non-small cell lung cancer(NSCLC).Method A total of 80 patients with advanced NSCLC were divided into control group(n=40,treated with CT guided radiofrequency ablation+chemotherapy)and observation group(n=40,treated with CT guided radiofrequency ablation+EGFR-TKI targeted therapy).The specific symptom[European Organization for Research and Treatment of Cancer quality of life questionnaire core 30(EORTC QLQ-C30)],tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),neuron specific enolase(NSE)],immune function(CD3^(+),CD4^(+)and CD4^(+)/CD8^(+))and adverse reactions were compared between the two groups.Result After treatment,the scores of pain,diarrhea,fatigue,sleep disorder,constipation,nausea and vomiting in the two groups were lower than those before treatment,with lower scores in the observation group than those in the control group(P<0.05).After treatment,the CEA,CA125 and NSE levels in the two groups were lower than those before treatment,with lower levels in the observation group than those in the control group(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the two groups were higher than those before treatment,with higher levels in the observation group than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P<0.01).Conclusion EGFR-TKI targeted therapy combined CT guided radiofrequency ablation can effectively improve the clinical symptoms and immune function of patients with advanced NSCLC,reduce the level of tumor markers,with higher safety and significant efficacy.